|
|
|
| Effect of Bevacizumab Combined with FOLFOX on the Expression of VEGF, MMPs and COX-2 in Patients with Advanced Colorectal Cancer |
| XIAO Qi, WANG Xiao-jie, XIE Ming-shui |
| Department of Oncology,No.92 Hospital of PLA,Nanping,Fujian 353000,China |
|
|
|
Abstract 【Objective】 To investigate the effect of bevacizumab combined with 5- fluorouracil (5-Fu) + oxaliplatin (L-OHP) + leucovorin (LV) (FOLFOX) chemotherapy on the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMPs) and cyclooxygenase-2 (COX-2) in patients with advanced colorectal cancer. 【Methods】A total of 90 patients with advanced colorectal cancer were equally divided into the control group and the observation group, with 45 cases in each. Both groups were treated with FOLFOX chemotherapy; however, the observation group was additionally treated with bevacizumab. The therapeutic effect was compared between the two groups. The changes in serum VEGF, MMPs and COX-2 were determined before and after treatment. The changes in quality of life before and after treatment were evaluated according to the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLC-CR37) scale. The incidence rates of side effects in the two groups were statistically analyzed. 【Results】① The total remission rate of the observation group was higher than that of the control group (P<0.05). ② After treatment, the expression levels of VEGF, COX-2, MMP-2 and MMP-9 in both groups were decreased, and the decrease in the observation group was significantly greater than that in the control group (P<0.05). ③ After treatment, the quality of life scores in both groups were increased (P<0.05), and the increase in the observation group was greater than that in the control group (P<0.05). ④ The main side effects in the two groups were grade Ⅰ~Ⅱ leukopenia, gastrointestinal reactions and anemia. There was no case of grade Ⅲ~Ⅳ side effects in the observation group. The incidence rates of different grades of side effects were slightly lower in the observation group than those in control group (P>0.05). 【Conclusion】The total remission rate of bevacizumab combined with FOLFOX chemotherapy is higher than that of routine FOLFOX treatment. The expression of VEGF, COX-2, MMP-2 and MMP-9 is significantly down-regulated. Patient life quality can be improved significantly and the drug tolerance is high as well.
|
|
|
|
|
|
|
|
[1] 徐阳.VEGF-C,VEGF-D和VEGFR-3在结直肠癌组织中的表达及临床意义[J].中国老年学杂志,2013,33(18):4432-4433.
|
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(1): 113-114. |
|
|
|
|
2016, Vol. 33 
